HIV : 4 generic Truvada allowed in France

Jeff Chiu/AP/SIPA

Published the 28.07.2017 at 17: 58

A A

Keywords :

VIHPrEPtruvada

The preventive treatment of HIV may well be less expensive in the weeks to come. At least one laboratory is ready to distribute a generic version of Truvada (emtricitabine/tenofovir) : the U.s. Mylan. As announced on 26 July, an authorisation for the placing on the market (AMM) european has been issued for this medication indicated in the treatment and prevention of HIV infection.

A patent by the end of the race

Three other laboratories are also in the starting blocks. Biogaran, EG and Zentiva have them also permission to produce a generic version of Truvada. Mylan is without doubt the most advanced : it has already announced the cost of its production. The box of 30 tablets will 179,90 euros. The brand is sold at a price of 406,86 euros per box.

The economy would be considerable for the health Insurance. Truvada is currently supported at 100 % – in prevention as in treatment of HIV infection. And in France, a quarter of hiv-positive patients receiving this molecule. Of the sick to which are added the approximately 3,000 beneficiaries of the PrEP declared at the beginning of the year 2017.

The month of July could prove to be crucial. Indeed, it is this month that expires on the patent of Truvada. But as stated in Gilead, contacted by Pourquoidocteur, ” in the country where the laboratory has supplementary protection Certificates (PPC) are valid, it extends our intellectual property rights until 2020 “.

France is one of the 12 countries under the ambit of this provision, which allows you to bypass the maximum limit of the patent, established 20 years. Get excited about immediately would be premature. As much as obtaining a marketing authorisation does not prejudge of an actual distribution, as specified by the national security Agency of the drug (MSNA) to Pourquoidocteur.